| Cancer type |
Gene name,
ChiPPI,
ChiTaRS |
Gene type
and analysis |
Description |
Network Features |
Mutational Features |
| Preferential Attachment Score |
Network Compactness value |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| BLCA | NAT1
|
oncogene
|
N-acetyltransferase 1 | 4.26614 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 346170 | | No of non-silent mutations in this gene across the individual set: | 4 | | No of patients with at least one nonsilent mutation: | 4 | | No of unique sites having a non-silent mutation: | 4 | | No of silent mutations in this gene across the individual set: | 0 | | No of non-silent mutations of type: Tp*C->(T/G): | 1 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 1 | | No of non-silent mutations of type: A->mut: | 2 | | No of non-silent mutations of type: indel+null: | 0 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.19 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.376 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.29 | | p-value for clustering + conservation: | 0.6 | | p-value (overall): | 0.582 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.354 |
|
|
|
| BLCA | NAT2
|
oncogene
|
N-acetyltransferase 2 | 4.23847 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 345774 | | No of non-silent mutations in this gene across the individual set: | 1 | | No of patients with at least one nonsilent mutation: | 1 | | No of unique sites having a non-silent mutation: | 1 | | No of silent mutations in this gene across the individual set: | 0 | | No of non-silent mutations of type: Tp*C->(T/G): | 1 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 0 | | No of non-silent mutations of type: A->mut: | 0 | | No of non-silent mutations of type: indel+null: | 0 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.848 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.768 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0 | | p-value for clustering + conservation: | 0 | | p-value (overall): | 0 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.848 |
|
|
|
| BLCA | ABCA1
|
oncogene
|
ATP binding cassette subfamily A member 1 | 1.34 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 2713874 | | No of non-silent mutations in this gene across the individual set: | 13 | | No of patients with at least one nonsilent mutation: | 13 | | No of unique sites having a non-silent mutation: | 13 | | No of silent mutations in this gene across the individual set: | 3 | | No of non-silent mutations of type: Tp*C->(T/G): | 9 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 3 | | No of non-silent mutations of type: A->mut: | 0 | | No of non-silent mutations of type: indel+null: | 1 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.999 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.283 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.703 | | p-value for clustering + conservation: | 0.337 | | p-value (overall): | 0.651 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.93 |
|
|
|
| BLCA | ABCA3
|
oncogene
|
ATP binding cassette subfamily A member 3 | 1.67 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 1842762 | | No of non-silent mutations in this gene across the individual set: | 8 | | No of patients with at least one nonsilent mutation: | 8 | | No of unique sites having a non-silent mutation: | 8 | | No of silent mutations in this gene across the individual set: | 3 | | No of non-silent mutations of type: Tp*C->(T/G): | 3 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 2 | | No of non-silent mutations of type: A->mut: | 1 | | No of non-silent mutations of type: indel+null: | 2 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.995 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.629 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.323 | | p-value for clustering + conservation: | 0.0916 | | p-value (overall): | 0.163 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.457 |
|
|
|
| BLCA | ABL1
|
oncogene
|
ABL proto-oncogene 1, non-receptor tyrosine kinase | 5.80459 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 1330506 | | No of non-silent mutations in this gene across the individual set: | 9 | | No of patients with at least one nonsilent mutation: | 9 | | No of unique sites having a non-silent mutation: | 9 | | No of silent mutations in this gene across the individual set: | 5 | | No of non-silent mutations of type: Tp*C->(T/G): | 5 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 2 | | No of non-silent mutations of type: A->mut: | 1 | | No of non-silent mutations of type: indel+null: | 1 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 1 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.891 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.857 | | p-value for clustering + conservation: | 0.49 | | p-value (overall): | 1 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 1 |
|
|
|
| BLCA | ABL2
|
oncogene
|
ABL proto-oncogene 2, non-receptor tyrosine kinase | 5.13354 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 1431974 | | No of non-silent mutations in this gene across the individual set: | 7 | | No of patients with at least one nonsilent mutation: | 7 | | No of unique sites having a non-silent mutation: | 7 | | No of silent mutations in this gene across the individual set: | 3 | | No of non-silent mutations of type: Tp*C->(T/G): | 3 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 2 | | No of non-silent mutations of type: A->mut: | 1 | | No of non-silent mutations of type: indel+null: | 1 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 1 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.886 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.378 | | p-value for clustering + conservation: | 0.645 | | p-value (overall): | 0.571 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.891 |
|
|
|
| BLCA | ABO
|
oncogene
|
ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) | 5.23 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 310219 | | No of non-silent mutations in this gene across the individual set: | 0 | | No of patients with at least one nonsilent mutation: | 0 | | No of unique sites having a non-silent mutation: | 0 | | No of silent mutations in this gene across the individual set: | 0 | | No of non-silent mutations of type: Tp*C->(T/G): | 0 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 0 | | No of non-silent mutations of type: A->mut: | 0 | | No of non-silent mutations of type: indel+null: | 0 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 1 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 1 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0 | | p-value for clustering + conservation: | 0 | | p-value (overall): | 0 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 1 |
|
|
|
| BLCA | ABR
|
oncogene
|
active BCR-related | 5.56 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 956596 | | No of non-silent mutations in this gene across the individual set: | 6 | | No of patients with at least one nonsilent mutation: | 6 | | No of unique sites having a non-silent mutation: | 6 | | No of silent mutations in this gene across the individual set: | 5 | | No of non-silent mutations of type: Tp*C->(T/G): | 4 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 1 | | No of non-silent mutations of type: A->mut: | 0 | | No of non-silent mutations of type: indel+null: | 1 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.996 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.94 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.551 | | p-value for clustering + conservation: | 0.406 | | p-value (overall): | 0.55 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.878 |
|
|
|
| BLCA | ACADM
|
oncogene
|
acyl-CoA dehydrogenase, C-4 to C-12 straight chain | 5.23 | 1 |
|
|
| No of sequenced bases in this gene across the individual set: | 516506 | | No of non-silent mutations in this gene across the individual set: | 1 | | No of patients with at least one nonsilent mutation: | 1 | | No of unique sites having a non-silent mutation: | 1 | | No of silent mutations in this gene across the individual set: | 1 | | No of non-silent mutations of type: Tp*C->(T/G): | 0 | | No of non-silent mutations of type: Tp*C->A: | 0 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 1 | | No of non-silent mutations of type: A->mut: | 0 | | No of non-silent mutations of type: indel+null: | 0 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.91 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.986 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0 | | p-value for clustering + conservation: | 0 | | p-value (overall): | 0 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.91 |
|
|
|
| BLCA | ACTB
|
oncogene
|
actin beta | 5.97407 | 0.497 |
|
|
| No of sequenced bases in this gene across the individual set: | 452982 | | No of non-silent mutations in this gene across the individual set: | 20 | | No of patients with at least one nonsilent mutation: | 17 | | No of unique sites having a non-silent mutation: | 16 | | No of silent mutations in this gene across the individual set: | 4 | | No of non-silent mutations of type: Tp*C->(T/G): | 9 | | No of non-silent mutations of type: Tp*C->A: | 1 | | No of non-silent mutations of type: (A/C/G)p*C->mut: | 6 | | No of non-silent mutations of type: A->mut: | 0 | | No of non-silent mutations of type: indel+null: | 4 | | No of non-silent mutations of type: double_null: | 0 | | p-value for the observed amount of non-silent mutations being elevated in this gene: | 0.000548 | | p-value for the observed non-silent/silent ratio being elevated in this gene: | 0.209 | | p-value for enrichment of mutations at evolutionarily most-conserved sites in gene: | 0.48 | | p-value for clustering + conservation: | 0.576 | | p-value (overall): | 0.682 | | q-value False Discovery Rate (Benjamini-Hochberg procedure): | 0.00332 |
|
|
|
